

Reversible posterior leukoencephalopathy syndrome following sunitinib therapy: a case report and review of the literature

Khurum H Khan, Audrey Fenton, Eimer Murtagh, James JA McAleer, and Alison Clayton

ABSTRACT

Sunitinib is one of the standard targeted therapies used in metastatic renal cell carcinoma. It is generally a reasonably tolerated oral systemic therapy but can be occasionally associated with life-threatening toxicities. We present a case of reversible posterior encephalopathy, which is a rare but recognised side effect of the treatment.

Key words: reversible posterior leukoencephalopathy syndrome, sunitinib.

Correspondence to: Khurum H Khan, Drug Development Unit, Royal Marsden Hospital, Sutton, London SM2 5PT, United Kingdom.
email khurum.khan@icr.ac.uk

Received October 18, 2011;
accepted February 14, 2012.